Related Experiment Videos
Prognostic value of morphometry in papillary thyroid carcinoma
R A Ambros1, R C Trost, A Y Campbell
1Department of Pathology, Beth Israel Medical Center, Newark, NJ.
Human Pathology
|March 1, 1989
Summary
Morphometric analysis, including nuclear anisotropism and cellularity, significantly predicts papillary thyroid carcinoma recurrence. This method offers prognostic information beyond standard indicators for better patient evaluation.
Area of Science:
- Oncology
- Pathology
- Medical Imaging
Background:
- Papillary thyroid carcinoma (PTC) prognosis is typically assessed using standard indicators.
- The added value of quantitative histopathology (morphometrics) remains to be fully elucidated.
Purpose of the Study:
- To evaluate the prognostic significance of morphometric parameters in papillary thyroid carcinoma.
- To determine if morphometrics improve recurrence prediction beyond established prognostic factors.
Main Methods:
- Retrospective analysis of 28 papillary thyroid carcinoma cases with a mean follow-up of 47 months.
- Comparison of standard prognostic indicators (age, sex, lymph node status, tumor size, encapsulation) with morphometric features.
- Univariate and stepwise incremental analyses to identify significant predictors of tumor recurrence.
Main Results:
- Tumor recurrence was associated with nuclear anisotropism (estimated nuclear area standard deviation [ENASD]) and tumor size in univariate analysis.
- Stepwise analysis revealed ENASD and cellularity mean index (CMI) as significant independent predictors of recurrence.
- Patients with ENASD > 17 microns2 and CMI > 40% had a 55% recurrence rate versus 5% for others (P = .0001).
Conclusions:
- Morphometric analysis, specifically ENASD and CMI, significantly correlates with tumor recurrence in papillary thyroid carcinoma.
- Quantitative histopathology provides prognostic information not obtainable through standard methods.
- Morphometrics can enhance the histopathological evaluation and prognostic assessment of papillary thyroid carcinoma.